--- title: "What’s Going On With Tempus AI Stock on Monday?" type: "News" locale: "en" url: "https://longbridge.com/en/news/296819332.md" description: "Tempus AI (TEM) stock pulled back 6.78% to $67.76 on Monday, reversing a recent 20% surge. The prior rally was driven by Phase 3 data for Merck and Moderna’s mRNA therapy, highlighting Tempus's $1.5 billion Personalis deal. Additionally, the FDA granted 510(k) clearance for Tempus's ECG-PH AI tool to detect pulmonary hypertension. Analysts maintain a Hold consensus with an average price target of $61.27, though BTIG recently raised its forecast to $80." datetime: "2026-08-24T18:02:51.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296819332.md) - [en](https://longbridge.com/en/news/296819332.md) - [zh-HK](https://longbridge.com/zh-HK/news/296819332.md) generator: "portal-rs" --- # What’s Going On With Tempus AI Stock on Monday? **Tempus AI Inc** (NASDAQ:TEM) stock is trading lower on Monday as the stock is pulling back from an approximately 20% surge over the last week. ## Personalis Deal Draws Attention The recent surge in the stock was driven by momentum from Phase 3 INTerpath-001 results from **Merck & Co**. **Inc.** (NYSE:MRK) and **Moderna Inc**. (NASDAQ:MRNA) of intismeran autogene (a custom mRNA neoantigen therapy) paired with Keytruda for advanced melanoma. The data puts a spotlight on the company’s $1.5 billion **Personalis Inc.** (NASDAQ:PSNL) deal. **Read Also: Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight** Moderna uses Personalis’ sequencing platform to analyze tumor tissue and identify specific neoantigens needed to manufacture individualized doses. ## Tempus AI Gets FDA Clearance For Pulmonary Hypertension Tool On Monday, Tempus received FDA 510(k) clearance for ECG-PH, an AI product intended to detect signs of pulmonary hypertension from a standard ECG. The clearance adds pulmonary hypertension to the company’s FDA-cleared AI products alongside atrial fibrillation and low ejection fraction. ## Analyst Consensus & Recent Actions The stock carries a Hold rating with an average price forecast of $61.27. Recent analyst moves include: - **BTIG**: Buy (Raises Forecast to $80.00) (August 20) - **Piper Sandler**: Neutral (Lowers Forecast to $56.00) (August 4) - **BTIG**: Buy (Lowers Forecast to $70.00) (August 3) ## Top ETFs Holding Tempus AI (TEM) - **ARK Innovation ETF** (NYSE:ARKK): 4.94% Weight - **ARK Genomic Revolution ETF** (BATS:ARKG): 6.86% Weight - **Wisdomtree BioRevolution Fund** (NASDAQ:WDNA): 2.52% Weight ## How Tempus AI Ranks On Momentum Versus The Market Below is the Benzinga Edge scorecard for Tempus AI, highlighting its strengths and weaknesses compared to the broader market: - **Momentum**: Bullish (Score: 83.09) — The stock is still screening as a momentum name despite today’s sharp pullback. **The Verdict:** Tempus AI’s Benzinga Edge signal reveals a momentum-driven story, with the scorecard emphasizing trend strength more than fundamentals. For longer-term traders, that typically means risk management around support/resistance matters more than trying to “average” the move on volatile days. **TEM Stock Price Activity:** Tempus AI shares were down 6.78% to $67.76 at the time of publication on Monday, according to Benzinga Pro data. **Read Also: EU Tariffs Threaten Temu Margins After US Trade Squeeze** *Photo courtesy: Piotr Swat via Shutterstock* ### Related Stocks - [TEM.US](https://longbridge.com/en/quote/TEM.US.md) - [TEMT.US](https://longbridge.com/en/quote/TEMT.US.md) - [MRK.US](https://longbridge.com/en/quote/MRK.US.md) - [PSNL.US](https://longbridge.com/en/quote/PSNL.US.md) - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) - [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md) - [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md) - [PFE.US](https://longbridge.com/en/quote/PFE.US.md) - [BNTX.US](https://longbridge.com/en/quote/BNTX.US.md) - [ARKK.US](https://longbridge.com/en/quote/ARKK.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [WDNA.US](https://longbridge.com/en/quote/WDNA.US.md) ## Related News & Research - [Moderna (NASDAQ:MRNA) CFO Sells $4,685,093.64 in Stock](https://longbridge.com/en/news/298963121.md) - [Tempus AI wins up to $9.5 million ARPA-H ADVOCATE award for autonomous heart failure agent](https://longbridge.com/en/news/298498403.md) - [How Cathie Wood's fund gave us a back door to Moderna's breakthrough](https://longbridge.com/en/news/298769510.md) - [Amundi Reduces Stock Holdings in Moderna, Inc. $MRNA](https://longbridge.com/en/news/298693237.md) - [Moderna CFO James M. Mock disposes of 34,836 common shares worth $4.68 million](https://longbridge.com/en/news/298959314.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**